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Abstract 
 
Gramicidin A (GA) is a channel-forming ionophore that renders biological membranes 
permeable to specific cations which disrupts cellular ionic homeostasis.  It is a well-known 
antibiotic, however it’s potential as a therapeutic agent for cancer has not been widely 
evaluated.  In two recently published studies, we showed that GA treatment is toxic to cell 
lines and tumor xenografts derived from renal cell carcinoma (RCC), a devastating disease 
that is highly resistant to conventional therapy.  GA was found to possess the qualities of 
both a cytotoxic drug and a targeted angiogenesis inhibitor, and this combination 
significantly compromised RCC growth in vitro and in vivo.  In this review, we summarize 
our recent research on GA, discuss the possible mechanisms whereby it exerts its anti-
tumor effects, and share our perspectives on the future opportunities and challenges to the 
use of GA as a new anticancer agent. Copyright: The Authors. 
 
Received: 03 January 2015; Accepted after revision: 15 January 2015; Published: 18 January 2015 
 
Author for correspondence: Ayyappan K. Rajasekaran, PhD, Therapy Architects, LLC, Wilmington, DE 19810, 
USA. E-mail: raj@therapyarchitects.com or arakaran687@gmail.com 
 
How to cite: David JM, Rajasekaran AK. Gramicidin A:  A New Mission for an Old Antibiotic. Journal of Kidney 
Cancer and VHL 2015;2(1):15-24. Doi: http://dx.doi.org/10.15586/jkcvhl.2015.21 
 
Introduction 
 
 
The plasma membrane physically separates 
the intracellular components of a cell from 
the extracellular environment, and its 
integrity is absolutely essential to sustain 
cellular functions.  Living cells carefully 
control their intracellular ionic milieu in 
order to regulate virtually all aspects of 
cellular biology, including membrane 
potential, cell volume, cellular pH, solute 
transport, metabolism, proliferation, 
survival, and signaling.  Disruption of 
transmembrane ion concentration 
gradients compromises the ability of cells 
to properly regulate their internal 
environment (1), and drugs which have this 
effect are known as ionophores.  These 
drugs are classified on the basis of their 
mechanism of action; mobile-carriers 
complex with metal cations to shield their 
hydrophilic charge from the hydrophobic 
interior of the lipid bilayer, and channel-
formers insert into the membrane to form 
hydrophilic pores that permit the rapid 
passage of select cations through 
membranes.  Many ionophores are 
produced naturally by various 
microorganisms in order to defend against 
competing microbes, and these drugs 
exhibit broad-spectrum antibiotic 
properties against Gram-positive bacteria, 
fungi, parasites, and viruses (2). 
Ionophores have traditionally found utility 
as antibiotics in veterinary medicine and as 
growth-promoting feed additives for 
agriculture (1, 2), but research over the 
past decade has now recognized that they 
also possess extraordinary anticancer 
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properties.  The vast majority of this work 
has focused on the mobile-carriers 
monensin and salinomycin.  These agents 
have been shown to induce antiproliferative 
and cytotoxic effects, overcome therapy 
resistance, target cancer stem-like cells, 
and disrupt specific oncogenic signaling 
pathways in a diverse array of cancer types 
(reviewed in (2-5)).  Furthermore, 
salinomycin has been used in a small 
"first-in-man" pilot study with two patients.  
It was reported to induce tumor/metastasis 
regression, partial clinical response, and 
decreased levels of circulating tumor 
markers without any of the severe and 
long-term side effects that are commonly 
observed with conventional 
chemotherapeutics (4).  Continued clinical 
development of salinomycin is ongoing, and 
in 2012, the pharmaceutical companies 
Eisai and Verastem joined together to 
develop a “proprietary analog of 
salinomycin” to use as a Wnt inhibitor and 
anti-cancer stem cell drug for breast 
cancer.  
In contrast to the mobile-carriers, the 
potential anticancer properties of channel-
formers have been largely overlooked.  
Gramicidin A (GA) is the simplest and best-
characterized channel-forming ionophore.  
It was the very first antibiotic to be isolated 
and used in a clinical setting, and its initial 
success paved the way for the clinical 
development of penicillin and the dawn of 
the antibiotic era (6).  Structurally, GA is a 
short linear peptide of 15 alternating L- 
and D- amino acids with a formyl group at 
the N-terminus and ethanolamine at the C-
terminus.  GA is extremely hydrophobic, 
and within biological membranes two GA 
monomers dimerize end-to-end to form an 
unusual β-helix nanopore that spans the 
membrane (7) (Figure 1A).  Water and 
inorganic monovalent cations can freely 
diffuse through the channel formed by GA 
dimers, and in biological systems this 
results in Na+ influx/K+ efflux, membrane 
depolarization, osmotic swelling, and cell 
lysis (7, 8) (Figure 1B).  GA is well known 
to display potent broad-spectrum antibiotic 
activity (9-12), and we can now confirm 
that it also exhibits compelling anticancer 
properties that are both similar to, and 
distinct from, the mobile-carrier 
ionophores. 
Gramicidin A is cytotoxic 
In our initial study (13), we evaluated the 
cytotoxicity of GA using a panel of human 
cancer cell lines derived from renal cell 
carcinoma (RCC).  RCC is a relatively rare 
but deadly disease that is histologically 
heterogeneous and highly resistant to both 
chemotherapy and radiation.  The 5-year 
disease-specific survival rate for invasive 
RCC is only 10% (14, 15).  We found that 
treatment with GA decreased the viability 
of all six of the RCC cell lines tested at 
submicromolar concentrations (all IC50 < 
1.0μM).  GA was uniformly toxic regardless 
of histological subtype or the expression of 
various molecular markers of relevance to 
RCC pathophysiology.  This finding 
indicates that GA may be effective in 
multiple RCC subtypes, which is important 
because there are as yet no established 
therapies for the more rare subtypes of 
RCC (papillary, chromophobe, collecting 
duct carcinoma, etc.).  When we compared 
GA to the ionophore monensin, a mobile-
carrier with similar cation selectivity, we 
found that GA reduced cell viability equal 
to or even greater than monensin 
depending on the cell line tested.  However, 
further examination revealed that whereas 
monensin provoked apoptotic responses in 
treated cells, GA induced cell death 
through a necrotic mechanism that was 
associated with profound ATP depletion 
elicited by a blockade of both the oxidative 
phosphorylation and glycolytic metabolic 
pathways.  GA was also found to effectively 
suppress tumor growth in vivo. 
Collectively, this work demonstrated that 
perturbation of Na+ and K+ homeostasis by 
GA impairs cellular metabolism and starves 
cancer cells of energy.  Precisely how this 
occurs remains to be fully determined, 
however our evidence supports a model in 
which oxidative stress is a potential link 
between GA and energy depletion (Figure 
2). Oxidative stress appears to be a 
common feature of ionophores as both 
monensin and salinomycin were reported 
to increase the production of reactive 
oxygen species (ROS) (16-19). Cells respond 
to oxidative stress by upregulating ROS 
detoxifying pathways, and nicotinamide 
adenine dinucleotide phosphate (NADPH) is 
a crucial coenzyme that is required for the 
regeneration of reduced glutathione that is 
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Figure 1.  Mechanism of action of gramicidin A.  (A) Gramicidin monomers form a β-helix 
conformation within membranes.  Dynamic dimerization of two monomers forms the functional 
channel, which consequently induces local membrane deformation.  (B) Cells maintain a low 
concentration of intracellular Na+ and a high concentration of intracellular K+ relative to the 
extracellular environment.  Formation of the gramicidin channel (green cylinder) upsets this balance 
by permitting the passive diffusion of these cations along their respective concentration gradients 
(arrows) resulting in Na+ influx and K+ efflux. 
 
 
used to detoxify ROS (20).  AMP-activated 
protein kinase (AMPK) was recently shown 
to increase NADPH production via 
enhancing glycolytic flux (21), and we 
observed both increased AMPK activation 
and a transient initial increase in glycolysis 
in GA-treated cells.  If GA does in fact 
induce oxidative stress, then it is possible 
that AMPK responds by upregulating 
glycolysis to enhance NADPH production in 
order to alleviate this stress.  
 
In addition, oxidative stress by ionophores 
damages DNA (16-19).  Cells use the 
enzyme poly (ADP-ribose) polymerase 
(PARP) to signal damaged DNA by 
catalyzing the addition of ADP-ribose 
moieties to nuclear proteins at the site of 
damage in a reaction that consumes NAD+ 
(22).  In the case of extensive DNA damage, 
PARP can become overstimulated and 
deplete cellular NAD+ (22).  Glycolysis 
depends upon the reduction of NAD+ to 
NADH, and loss of NAD+ blocks glycolysis 
(22).  We did not observe PARP cleavage 
(inactivation) in GA-treated cells, but we 
did observe a marked decrease in cellular 
redox activity and eventual loss of 
glycolytic activity, suggesting that NAD+ 
may have been depleted by treatment with 
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Figure 2:  Proposed model of GA cytotoxicity.  GA may induce oxidative stress, which can activate 
AMPK to increase glycolytic flux.  This in turn can increase NADPH production via the pentose 
phosphate pathway, and NADPH regenerates glutathione to detoxify ROS.  Oxidative stress also 
damages DNA leading to the activation of PARP.  Overactive PARP depletes NAD+, which inhibits 
glycolysis leading to ATP depletion and subsequent necrotic cell death. 
 
 
GA. Loss of glycolysis would impair NADPH 
production and rapidly deplete ATP, 
ultimately leading to necrotic cell death. 
This mechanism of bioenergetics 
catastrophe leading to necrosis has been 
reported for DNA damaging alkylating 
agents (e.g. nitrogen mustards) (23), 
suggesting that GA shares important 
characteristics with conventional 
chemotherapeutics. Experimental 
validation of this proposed model (Figure2) 
would provide key insights into the 
mechanism of cytoxicity by gramicidin A.  
 
Gramicidin A inhibits angiogenesis  
 
Hypoxia and RCC  
 
Oxygen deprivation is a common feature of 
solid tumors as the tumor micro 
environment is characterized by a steep 
oxygen concentration gradient that 
regularly experiences temporal fluctuations 
in oxygenation.  Accordingly, tumors 
exhibit many molecular and biochemical 
features associated with the cellular 
response to low oxygen (hypoxia), which is 
controlled by the transcription factor 
hypoxia-inducible factor (HIF).  Numerous 
functional investigations have revealed that 
HIF promotes tumor growth, 
vascularization, and metastatic spread, 
and a large body of clinical evidence has 
linked HIF activation with cancer 
progression, and reduced patient survival 
(24-26).  RCC tumors in particular display 
features associated with chronic hypoxia 
responses (27), and it is now recognized 
that constitutive activation of HIF is a key 
etiologic feature of RCC. 
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HIF exists as a heterodimer that consists of 
an oxygen-sensitive α-subunit and a 
constitutively expressed β-subunit (HIF-β) 
(28). Regulation of HIF activity is mediated 
by strict control of the protein levels of the 
α-subunits.  When oxygen levels are 
adequate (normoxia), HIF-α is rapidly 
hydroxylated and bound by the von Hippel-
Lindau tumor suppressor protein (VHL) 
which promotes the ubiquitylation and 
subsequent degradation of HIF-α (27).  
Conversely, HIF-α stabilizes in hypoxic 
conditions as O2 deprivation inhibits 
protein hydroxylation.  Constitutive 
activation of HIF occurs in RCC through 
the loss of VHL expression/activity in the 
clear cell subtype (ccRCC), and through 
additional VHL-independent means in 
other subtypes (14).  Anti-angiogenesis 
therapies that antagonize HIF function (e.g. 
sunitinib, sorafenib, bevacizumab, etc.) 
have succeeded in increasing progression-
free survival and quality of life for ccRCC 
patients, however durable and complete 
remissions remain rare (29).  
 
Gramicidin A Inhibits HIF  
 
Studies conducted over the past 10-15 
years have demonstrated that a diverse 
array of chemotherapeutic agents, 
including topoisomerase inhibitors, 
microtubule-targeting drugs, and 
anthracyclines, can inhibit HIF 
transcriptional activity (24).  Furthermore, 
low-dose cyclophosphamide given at more 
frequent intervals has been shown to block 
tumor angiogenesis (30).  Given the 
aforementioned cytotoxic similarities 
between GA and chemotherapy drugs, we 
sought to examine the effects of GA upon 
hypoxia responses in RCC cells.  We 
discovered that treatment of cells with GA 
reduced the expression of the HIF-1α and 
HIF-2α isoforms in both normoxic and 
hypoxic conditions.  This in turn 
suppressed HIF-dependent hypoxia 
responses and occurred even at doses 
lower than those used in our prior 
cytotoxicity studies.  Comparison of GA 
with the mobile-carriers monensin, 
valinomycin, and calcimycin showed that 
only GA elicited a dramatic and persistent 
decrease in HIF-1α and HIF-2α expression. 
These effects only occurred in VHL-positive 
but not VHL-negative cell lines, and 
mechanistic examination revealed that GA 
specifically upregulates the VHL tumor 
suppressor to accelerate the O2-dependent 
destabilization of HIF.  These effects were 
confirmed in vivo, as treatment with GA 
reduced the growth and angiogenesis in 
VHL-positive RCC tumors.  
 
VHL upregulation by Gramicidin A 
 
The anti-angiogenic effects of GA raise 
several provocative questions and 
possibilities.  First, precisely how 
perturbing the intracellular ionic milieu 
affects VHL expression is not fully 
understood.  GA exhibits similar sensitivity 
for Na+ and K+ (31) and induces the 
simultaneous influx of Na+ and efflux of K+ 
in living cells.  When we compared GA with 
three mobile-carrier ionophores, only 
valinomycin provoked a partial decrease in 
HIF expression.  Since valinomycin is 
highly selective for K+ over Na+ (32), this 
result suggests that increased VHL 
expression is due primarily to the loss of 
intracellular K+, assuming the mechanism 
of HIF downregulation is identical for both 
drugs.  Further experiments will be 
necessary to confirm this supposition.  
Second, our results showed that only VHL 
protein increased in GA-treated cells 
implying that either the translation of VHL 
transcripts or the stability of VHL protein 
was increased.  Factor(s) that regulate VHL 
mRNA translation have yet to be identified, 
but several factors are known to influence 
VHL protein stability.  VHL is stabilized 
when bound to its associated ubiquitin 
ligase components (elongins B and C, 
RBX1, cullin 2) (33), and GA may promote 
this binding.  Alternatively, several proteins 
are known to specifically target and 
destabilize VHL: 1) E2-EPF ubiquitin 
carrier protein is another ubiquitin ligase 
component that directly targets VHL for 
proteasomal degradation and is expressed 
in primary and metastatic tumors (34); 2) 
casein kinase 2 destabilizes VHL through 
phosphorylation of serines 33, 38, and 43 
and is upregulated in most human cancers 
(35); 3) transglutaminase 2 is a 
crosslinking enzyme that causes VHL 
degradation by polymerization and is also 
overexpressed in many cancers (36).  
Whether GA inhibits any of these cancer-
associated proteins to stabilize VHL 
expression remains to be determined. 
Third, our findings indicate that 
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upregulation of VHL by GA blocks tumor 
angiogenesis and growth, yet we found no 
relationship between VHL expression and 
in vitro viability in response to GA (13). 
This finding was actually not surprising as 
studies have reported that VHL 
overexpression in naturally VHL-deficient 
cell lines caused dramatic suppression of 
in vivo tumor formation and growth 
without concomitant inhibition of in vitro 
cell growth (37, 38).  However, exactly how 
much of the reduction in tumor growth by 
GA is due to direct cytotoxicity (VHL-
independent) as opposed to the blockade of 
tumor angiogenesis (VHL-dependent) is not 
yet known.  
 
Lastly, it has become increasingly apparent 
in recent years that VHL suppresses 
tumorigenesis not only through the 
downregulation of HIF, but also through a 
myriad of HIF-independent mechanisms.  
VHL has been shown to directly bind both 
fibronectin and collagen IV alpha 2 and 
promote the proper assembly of the 
extracellular matrix, and loss of VHL 
disrupts the normal tissue and 
extracellular matrix architecture in a way 
that better facilitates tumor growth, 
invasion, and blood vessel infiltration (39).  
VHL also downregulates integrins which 
prevent cell motility and invasion by 
preserving the cell-cell adhesions of both 
the tight and adherens junctions (39).  
Furthermore, VHL stabilizes microtubules 
at the cell periphery, which positively 
regulates the biogenesis and function of the 
primary cilium.  The primary cilium is a 
microtuble-based organelle found in all 
cells that functions as a chemo-, osmo-, 
and mechano-sensor of the extracellular 
environment, and its loss in VHL-deficient 
kidney cells leads to inappropriate 
proliferation and the formation of 
preneoplastic renal cysts (i.e. polycystic 
kidney disease) (39, 40).  Finally, VHL 
stabilizes the fellow tumors suppressor 
proteins p53 and Jade-1 (gene for 
apoptosis and differentiation in epithelia), 
which preserves DNA damage responses 
and inhibits oncogenic Wnt/β-catenin 
signaling, respectively (40, 41).  An exciting 
proposition to consider is whether 
upregulation of VHL by GA promotes these 
additional HIF-independent mechanisms to 
block tumor growth and development.  
Validation of this notion would broaden the 
therapeutic appeal of GA as a treatment for 
VHL-positive cancers of the kidney and 
other tissues alike.  
 
Future development of GA  
 
Generalized toxicity is a significant 
challenge to the development of ionophores 
as therapies for human cancer.  GA causes 
hemolysis and is toxic to the liver, kidney, 
meninges, and olfactory apparatus (7, 42), 
and polyether mobile-carrier ionophores 
are also toxic and elicit neurological side 
effects (1, 43).  However, a variety of 
normal and nonmalignant cells were 
reported to be less sensitive to mobile-
carrier ionophores (16-18, 44, 45) and 
murine xenograft experiments from ours 
and other investigators have demonstrated 
the in vivo efficacy of ionophores without 
significant side effects (46-50).  
Furthermore, salinomycin was shown to be 
effective in two human cancer patients 
without eliciting any severe toxicities (4).  
Nevertheless, a comprehensive 
understanding of effects of ionophore drugs 
upon cancer cells vs. normal tissues is 
currently lacking and will be necessary 
before clinical development can progress to 
a larger scale.  
 
The generalized toxicity of GA can be 
alleviated by intratumoral injection.  This 
method of administration improves the 
therapeutic index of drugs by concentrating 
the drug at the tumor site only to spare the 
rest of the body.  We found intratumoral 
injection of GA to be both safe and effective 
in our murine xenograft studies.  Through 
the use of X-ray computed tomography, 
intratumoral injection in the clinic is now 
possible for metastatic and/or inoperable 
tumors, and we suggest that wider use of 
the technique will allow agents such as GA 
to advance into clinical use more rapidly.  
 
Chemical modification or mutation of the 
GA peptide has proven effective at 
increasing microbial targeting and 
decreasing non-specific toxicity (7, 8, 51, 
52). Such mutagenesis approach could be 
utilized to identify a non-toxic but 
efficacious form of GA that could be used 
systemic delivery for treating tumors in in 
vivo.  Alternatively, encapsulation of GA in 
nanoparticles targeted to the tumor could 
be used to safely deliver GA for treatment 
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purposes.  A recent report by Wijesinghe et 
al. used a novel pH-sensitive liposomal 
approach to deliver encapsulated GA into 
the membranes of cancer cells, resulting in 
cancer cell death (53).  Such an approach 
could be used to target cancer cells within 
the acidic tumor microenvironment only, 
thereby reducing non-specific toxicity by 
sparing normal tissues.  
 
Conclusion  
 
GA, the channel-forming ionophore, has 
cytotoxic and antiangiogenic activities in 
RCC tumors.  The cytotoxic activity is due 
to ATP depletion, and the anti-angiogenic 
effect is due to the inhibition of HIF via the 
induction of endogenously expressed VHL.  
Our in vitro and in vivo studies strongly 
suggest that GA has the potential to be 
developed into a therapeutic agent for RCC 
and possibly other cancers.  
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